{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-22-000184","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.558210+00:00","generated_at":"2026-06-22T10:30:54.832111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Artivion Q3 revenue $76.8M (+6% GAAP, +11% constant currency); net loss $0.34/share","bullets":["Revenue $76.8M, up 6% GAAP and 11% constant currency vs Q3 2021.","On-X revenues up 17% GAAP and 19% constant currency; tissue processing up 13% constant currency.","Net loss ($13.7M) or ($0.34)/share vs net income $10.6M ($0.26) in Q3 2021. Includes $4.7M PROACT Xa termination charge and $3.7M FX loss.","Non-GAAP net loss ($1.9M) or ($0.05)/share vs ($1.2M) ($0.03) prior year.","2022 outlook: narrowing constant currency revenue growth to 9-10%; full-year revenue expected $313M-$316M."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-22-000184","json":"https://secwatch.observer/filing/0000784199-22-000184.json","markdown":"https://secwatch.observer/filing/0000784199-22-000184.md","text":"https://secwatch.observer/filing/0000784199-22-000184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000184/0000784199-22-000184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000184/aort-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:30:54.832111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d991fa0d2273cc61ff455d89b0658562727dba2","claim":"ARTIVION, INC. reported third quarter ended September 30, 2022 results: revenue $76.8 million, net income ($13.7) million, or ($0.34) per fully diluted common share, EPS ($0.34) per fully diluted common share. Guidance reaffirmed.","evidence_excerpt":"Total revenues for the third quarter of 2022 were $76.8 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000184/0000784199-22-000184-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$76.8 million"},{"label":"Net income","value":"($13.7) million, or ($0.34) per fully diluted common share"},{"label":"EPS","value":"($0.34) per fully diluted common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}